Inotiv, Inc. NOTV
We take great care to ensure that the data presented and summarized in this overview for Inotiv, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NOTV
View all-
Silverback Asset Management LLC Chapel Hill, NC1.33MShares$5.05 Million18.57% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.3MShares$4.95 Million0.01% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.27MShares$4.82 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.09MShares$4.13 Million0.0% of portfolio
-
Ubs Group Ag614KShares$2.33 Million0.0% of portfolio
-
Vantage Point Financial LLC Lisle, IL337KShares$1.28 Million0.75% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny304KShares$1.16 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny288KShares$1.09 Million0.0% of portfolio
-
Kpp Advisory Services LLC Louisville, KY275KShares$1.05 Million0.27% of portfolio
-
Jane Street Group, LLC New York, NY241KShares$914,3560.0% of portfolio
Latest Institutional Activity in NOTV
Top Purchases
Top Sells
About NOTV
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Insider Transactions at NOTV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 18
2025
|
Robert Leasure Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
73,617
-7.15%
|
$220,851
$3.82 P/Share
|
Feb 18
2025
|
John E Sagartz Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,113
-0.3%
|
$6,339
$3.94 P/Share
|
Feb 18
2025
|
Beth Taylor Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,370
-3.88%
|
$17,480
$4.01 P/Share
|
Feb 18
2025
|
Jeffrey Brennan Freeman VP-Finance & Corp. Controller |
SELL
Open market or private sale
|
Direct |
1,339
-4.65%
|
$5,356
$4.04 P/Share
|
Feb 03
2025
|
Jeffrey Arthur Krupp Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
472
-1.63%
|
$1,888
$4.18 P/Share
|
Jan 31
2025
|
Robert Leasure Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
22,700
-2.16%
|
$90,800
$4.15 P/Share
|
Jan 31
2025
|
Jeffrey Arthur Krupp Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
2,036
-6.55%
|
$8,144
$4.48 P/Share
|
Jan 31
2025
|
John E Sagartz Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,118
-0.3%
|
$8,472
$4.48 P/Share
|
Jan 31
2025
|
Beth Taylor Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,054
-1.79%
|
$8,216
$4.46 P/Share
|
Dec 19
2024
|
David Landman Director |
BUY
Open market or private purchase
|
Direct |
23,529
+11.74%
|
$94,116
$4.25 P/Share
|
Dec 10
2024
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+15.64%
|
$120,000
$4.75 P/Share
|
Dec 10
2024
|
Nigel Brown Director |
BUY
Open market or private purchase
|
Direct |
7,500
+10.27%
|
$30,000
$4.26 P/Share
|
Dec 06
2024
|
David Landman Director |
BUY
Open market or private purchase
|
Direct |
100,000
+39.48%
|
$400,000
$4.14 P/Share
|
Dec 06
2024
|
Michael J Harrington Director |
BUY
Open market or private purchase
|
Direct |
10,000
+21.05%
|
$30,000
$3.98 P/Share
|
Aug 10
2024
|
Robert Leasure Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+22.17%
|
-
|
Aug 10
2024
|
David Landman Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+34.03%
|
-
|
Aug 10
2024
|
John Gregory Beattie Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.18%
|
-
|
Aug 10
2024
|
R Matthew Neff Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+19.2%
|
-
|
Aug 10
2024
|
Nigel Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+32.15%
|
-
|
Aug 10
2024
|
Adrian Hardy Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+37.44%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 578K shares |
---|---|
Open market or private purchase | 171K shares |
Open market or private sale | 111K shares |
---|